|
ALLERGY/ASTHMA
Cost Studies
|
PAA1 |
LEVOCETIRIZINE REDUCES THE COST OF PER AND ITS CO-MORBIDITIES
FOR SOCIETY AND EMPLOYERS
Bachert C1,
Demarteau N2
1 Ghent University Hospital, Belgium; 2
UCB pharma, Braine-l’Alleud, Belgium |
|
PAA2 |
PUBLIC HEATH
SYSTEM EXPENSES ON CHILDREN’S ATOPIC DERMATITIS TREATMENT IN
VLADIVOSTOK CITY
Derkach V, Prosekova E
Far East Branch of Scientific Research Institute of Clinic
Immunology, Vladivostok, Russia |
|
PAA3 |
RESOURCE USE
IN PATIENTS WITH EXACERBATIONS OF ASTHMA WITH DIFFERENT
UNDERLYING DEGREES OF SEVERITY IN FIVE EUROPEAN COUNTRIES
Piercy J1, Benford M2, Milligan G2,
Karavali M2
1 Adelphi Group, Bollington, Cheshire, UK; 2
Adelphi Group Products, Bollington, Cheshire, UK |
|
PAA4 |
A
COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS
OF SALMETEROL AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1, Plisko R1, Landa K1,
Glogowski C2, Gierczynski J2
1 HTA Consulting, Krakow, Poland; 2
GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland |
|
PAA5 |
A
COMPARATIVE ANALYSIS OF EFFICACY, SAFETY AND COST-EFFECTIVENESS
OF FLUTICASONE AND MONTELUCAST IN THERAPY OF BRONCHIAL ASTHMA
Hetnal M1,
Plisko R1, Landa K1, Glogowski C2,
Gierczynski J2
1 HTA Consulting, Krakow, Poland; 2
GlaxoSmithKline Pharmaceuticals S.A, Warszawa, Poland |
Health Policy Studies
|
PAA6 |
IMPACT OF A
DISEASE MANAGEMENT PROGRAM ON CONTROL OF ASTHMA IN NORMANDY
Launois R1, Salmeron S2, Lançon F3,
Perez V4, Gailhardou M3, Roy M4,
Magar Y5, Queniart-Stojanovic M3, Godard P6
1 REES France, Paris, France; 2 Hopital
Saint Joseph, Paris, France; 3 Fedialis Medica Groupe
GSK, Marly Le Roi, France; 4 Caisse Primaire
D’Assurance Maladie D’Evreux, Evreux, France; 5
EduSanté, Vanves, France; 6 Centre Hospitalier
Universitaire (C.H.U), Montpellier, France |
Methods
|
PAA7 |
A COMPARISON
OF TWO APPROACHES TO ESTIMATE ANNUAL MEDICATION COSTS IN THE
KORA ASTHMA AND ALLERGY STUDY
Holle R, Stark R, Behrend C, John J
GSF - Research Centre for Environment and Health, Neuherberg,
Germany |
|
PAA8 |
WITHDRAWN |
|
PAA9 |
WITHDRAWN |
ARTHRITIS
Cost Studies
|
PAR1 |
THE BURDEN
OF ANKYLOSING SPONDYLITIS IN AUSTRALIA: AN EPIDEMIOLOGICAL AND
COST OF ILLNESS MODEL
Stynes G1, Adams J2,
Tilden D1, Garrett S3, Wilson J2
1 M-TAG Limited, Hammersmith, UK; 2 M-TAG
Pty Limited, Chatswood, NSW, Australia; 3
Schering-Plough Pty Limited, Baulkham Hills, Australia |
|
PAR2 |
THE TOTAL
COST OF TREATMENT AND THE COST-EFFECTIVENESS OF VALDECOXIB VS
DICLOFENAC IN THE TREATMENT OF PATIENTS WITH OSTEOARTHRITIS (OA)
OF THE HIP AND/OR KNEE
von Scheele B1, Davis KH2, Gaffney
L3, Niculescu L4, Verburg KM5
1 RTI Health Solutions, Södra Sandby, Sweden; 2
RTI Health Solutions, Research Triangle Park, NC, USA; 3
RTI Health Solutions, Manchester, UK; 4 Pfizer Inc,
New York, NY, USA; 5 Pfizer Inc, Ann Arbor, MI, USA |
|
PAR3 |
QUANTIFYING
DISEASE SEVERITY AS A DETERMINANT OF COSTS AND QUALITY OF LIFE
IN PATIENTS WITH ANKYLOSING SPONDYLITIS IN AUSTRALIA
Tilden D1, Stynes G1, Adams J2,
Garrett S3
1 M-TAG Limited, Hammersmith, UK; 2 M-TAG
Australia Pty Ltd, Chatswood, NSW, Australia; 3
Schering-Plough Pty Limited, Baulkham Hills, Australia |
|
PAR4 |
THE COART
STUDY: THE COST OF OSTEOARTHRITIS IN FRANCE BETWEEN 1991 AND
2002
Le Pen C1, Reygrobellet C1,
Gerentes I2
1 Aremis Consultants and Paris Dauphine University,
Paris, France; 2 Negma-Lerads Laboratories, Paris,
France |
|
PAR5 |
MESSAGE: AN
OBSERVATIONAL POST-LAUNCH STUDY TO ASSESS EFFECTIVENESS AND COST
OF SUPLASYN® IN PATIENTS WITH KNEE OSTEOARTHRITIS
Le Pen C1, Ligier M2, Priol G2,
Maurel F2, Bacri AM3, Giret d’Orsay G3,
Riviere M4, Bard H5, Mazieres B6
1 Aremis Consultants and Paris Dauphine University,
Paris, France; 2 Aremis Consultants, Paris, France;
3 Chiesi, France; 4 Bioniche, Canada;
5 Rheumatologist, Paris; 6 Rheumatology
Department Rangueil Hospital, Toulouse, France |
|
PAR6 |
ECONOMIC
EVALUATION OF THERAPY WITH NSAID AND WITH COX-2 IN SUBJECTS AGED
66 YEARS OR MORE
Santoni L1, Da Deppo L2, Mantovani
LG1
1 University of Milan, Milan, Italy; 2
Pfizer Italia srl, Rome, Italy |
|
PAR7 |
FIBROMYALGIA
COST OF CARE
de Portu S1, Stisi S2, Fedrighi S1,
Rossetti F1, Mantovani LG1
1 University of Milan, Milan, Italy; 2
Hospital G.Rummo, Benevento, Italy |
|
PAR8 |
HEALTH
ECONOMIC EVALUATION OF PATIENTS WITH RHEUMATOID ARTHRITIS (RA)
TREATED WITH ADALIMUMAB
Vanoverbeke N1,
Annemans L1, Cauchie P2, Hendrickx
E2
1 HEDM, Meise, Belgium; 2 Abbott,
Ottignies, Belgium |
|
PAR9 |
A COST
MINIMISATION ANALYSE FOR STUDYING THE EFFICIENCY OF BIOLOGIC
THERAPIES (BT) IN RHEUMATOID ARTHRITIS (RA). OVERVIEW FOR THE
SPANISH SETTING
Badia X1, Serrano D1, Magaz S2
1 Health Outcomes Research Europe, Barcelona,
Barcelona, Spain; 2 Health Outcomes Policy and
Economics, Barcelona, Spain |
|
PAR10 |
PATTERNS OF
DOSING WITH ADALIMUMAB AMONG COMMERCIALLY INSURED PATIENTS
Ollendorf DA, Lidsky L, Zhao J
PharMetrics, Inc, Watertown, MA, USA |
|
PAR11 |
A COST
EFFICACY ANALYSIS ON ANTI-TNF THERAPY IN ANKYLOSING SPONDYLITIS
Singh G1, Tandon N2, Bala M2
1 Stanford University Medical School, Palo Alto, CA,
USA; 2 Centocor, Inc, Horsham, PA, USA |
|
PAR12 |
HOW ADEQUATE
DO RA-PATIENTS REPORT INDIRECT COSTS? – THE EXAMPLE OF A GERMAN
COHORT
Mittendorf T1, Merkesdal S2,
Greiner W1, Ruof J2
1 University of Hannover, Hannover, Germany; 2
Medical School of Hannover, Hannover, Germany |
|
PAR13 |
COST-EFFECTIVENESS OF VALDECOXIB COMPARED TO DICLOFENAC IN
PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN THE UK (UK) AND
GERMANY
Alten RH1, von Scheele B2, Gaffney
L3, Maciver F3, Niculescu L4
1 Schlossparkklinik, Berlin, Germany; 2
RTI Health Solutions, Södra Sandby, Sweden; 3 RTI
Health Solutions, Manchester, UK; 4 Pfizer Inc, New
York, NY, USA |
|
PAR14 |
COSTS OF RA
IN GERMANY ON A MICRO-COSTING LEVEL
Mittendorf T1, Ruof J2
1 University of Hannover, Hannover, Germany; 2
Medical School of Hannover, Hannover, Germany |
|
PAR15 |
A COMPARISON
OF COST OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF
RHEUMATOID ARTHRITIS IN ITALY: RESULTS OF THE IERI STUDY GROUP
De Portu S1, Ferraccioli G2,
Sarzi-Purrini P3, Fiocco U4, Montecucco C5,
Valesini A6, Canesi B7, Leardini G8,
Mecchia M9, Mantovani LG1
1 University of Milan, Milan, Italy; 2
Universitŕ Cattolica del Sacro Cuore, Rome, Italy; 3
Ospedale L. Sacco, Milano, Italy; 4 Universitŕ di
Padova, Padova, Italy; 5 Universitŕ di Pavia, IRCCS,
Policlinico S.Matteo, Pavia, Italy; 6 Universitŕ La
Sapienza, Policlinico Umberto I, Roma, Italy; 7
Ospedale Niguarda, Milano, Italy; 8 ULSS12 Venezia,
Venezia, Italy; 9 Wyeth, Aprilia, Aprilia, Italy |
|
PAR16 |
CO-PAYMENTS
IN RHEUMATOID ARTHRITIS OBSERVED IN A GERMAN COHORT
Mittendorf T1, Hülsemann JL2, Ruof
J2
1 University of Hannover, Hannover, Germany; 2
Medical School of Hannover, Hannover, Germany |
Quality of
Life/Utility/Preference Studies
|
PAR17 |
LINGUISTIC
ADAPTATION AND VALIDATION OF THE ARTHRITIS TREATMENT
SATISFACTION QUESTIONNAIRE (ARTS) INTO SPANISH
Ruiz M1, Campillo MA2, Monfort J2,
Pardo A1, Rejas J3,
Soto J3
1 Department of Methodology, College of Psychology,
Universidad Autónoma, Madrid, Spain; 2 Department of
Rheumatology, Hospital del Mar, Barcelona, Spain; 3
Pfizer SA, Alcobendas, Madrid, Spain |
|
PAR18 |
ASSESSMENT
OF HEALTH STATUS IN A NATIONAL SAMPLE OF U.S. OSTEOARTHRITIC
PATIENTS
Gandra SR, Lawrence LW, Humble LJ
The University of Louisiana at Monroe, Monroe, LA, USA |
|
PAR27 |
ASSESMENT OF
QUALITY OF LIFE (QOL) IN ADULTS WITH JUVENILE IDIOPATIC
ARTHRITIS (AIJ) DIAGNOSIS IN MéXICO: THE DISABILITY IMPACT
Guzmán Vázquez
S1, Soto-Molina H2, Cháidez-Rosales P3,
Ilizaliturri-Sánchez VM V3, Duarte-Salazar C3,
Nieves-Silva J3,
Valero González F3, Aguilera-Zepeda J3,
Garduńo Espinosa J2
1 Universidad Autónoma del Estado de México, Toluca,
Mexico; 2 Instituto Mexicano Seguro Social, Col.
Juarez, Mexico; 3 National Rehabilitation Center (CNR),
Col. Arenal de Guadalupe, Mexico |
|
PAR28 |
ASSESSING
INTANGIBLES IN BIOLOGIC THERAPIES FOR RHEUMATOID ARTHRITIS (RA).
A WILLINGNESS TO PAY (WTP) STUDY IN SPANISH PATIENTS.
Badia X1,
Serrano D1, Magaz S2
1 Health Outcomes Research Europe Group, Barcelona,
Spain; 2 Health Outcomes Policy and Economics,
Barcelona, Spain |
Health Policy Studies
|
PAR19 |
SURVEY OF
GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH RHEUMATOLOGISTS IN 2003
Thomas E1, Blotman F1, Myon E2,
Taieb C2
1 CHU Montpellier, Montpellier, France; 2
Health Economics & Quality of Life Dept, Boulogne-Billancourt,
France |
|
PAR20 |
PEOPLES
PREFERENCES FOR WHO SHOULD GET THE NEXT JOINT REPLACEMENT
Davies LM, Payne K, Fargher EA
University of Manchester, Manchester, UK |
|
PAR21 |
CROSS-SURVEY
OF RHEUMATOLOGISTS AND GP AWARENESS AND KNOWLEDGE OF
FIBROMYALGIA
Blotman F1, Thomas E1, Myon E2,
Taieb C2
1 CHU Montpellier, Montpellier, France; 2
Health Economics & Quality of Life Dept, Boulogne-Billancourt,
France |
|
PAR22 |
FIBROMYALGIA SYNDROM: A FRENCH EPIDEMIOLOGICAL SURVEY
Myon E, Taieb C
Health Economics & Quality of Life Dept, Boulogne-Billancourt,
France |
|
PAR23 |
SURVEY OF
GLOBAL FIBROMYALGIA MANAGEMENT BY FRENCH GENERAL PRACTITIONERS
Thomas E1, Blotman F1, Myon E2,
Taieb C2
1 CHU Montpellier, Montpellier, France; 2
Health Economics & Quality of Life Dept, Boulogne-Billancourt,
France |
Methods
|
PAR24 |
RELATIONSHIPS BETWEEN AGE, NUMBER OF PRESCRIPTIONS, AND
CO-MORBIDITIES AMONG VA PATIENTS
Raisch DW, Harris CL, Netravali S, Campbell H
VA Cooperative Studies Program, Albuquerque, NM, USA |
|
PAR25 |
CROSS-VALIDATION OF A NEW QUESTIONNAIRE DESIGNED TO PREDICT
FUTURE RISK OF NSAID-INDUCED GASTROINTESTINAL EVENTS
Livengood K, Ambegaonkar A, Craig T
Pfizer Inc, New York, NY, USA |
|
PAR26 |
COST-UTILITY
OUTCOMES SIMULATION MODEL FOR OSTEOARTHRITIS (OA) AND RHEUMATOID
ARTHRITIS (RA) PATIENTS (COSMO): DEVELOPMENT AND VALIDATION OF A
PHARMACOECONOMIC MODEL
Niculescu L1, Lising AW2, Neumann
PJ3
1 Pfizer Inc, New York, NY, USA; 2
Dymaxium Inc, Toronto, ON, Canada; 3 Harvard School
of Public Health, Boston, MA, USA |
CANCER
Cost Studies
|
PCN1 |
COST-EFFECTIVENESS OF APREPITANT GIVEN WITH STANDARD ANTIEMETICS
IN PATIENTS RECEIVING CHEMOTHERAPY IN OFFICE-BASED SETTINGS IN
GERMANY
Ehlken B1, Ihbe-Heffinger A2,
Bernard R2, Berger K3, Pellissier JM4,
Deuson R5
1 MERG, Medical Economics Research Group, Munich,
Germany; 2 Klinikum rechts der Isar, Technische
Universität München, Munich, Germany; 3 MERG Medical
Economics Research Group, Munich, Germany; 4 Merck
Research Laboratories, St. Charles, IL, USA; 5 Merck
& Co., Inc, Whitehouse Station, NJ, USA |
|
PCN2 |
COST-EFFECTIVENESS OF IMATINIB (GLEEVEC) AS FIRST-LINE TREATMENT
IN CHRONIC MYELOID LEUKEMIA (CML)
El Ouagari K1, Talbot W1, Baladi
JF2
1 Novartis Pharmaceuticals, Dorval, QC, Canada;
2 Novartos Pharmaceuticals, Florham Park, NJ, USA |
|
PCN3 |
COST-EFFECTIVENESS OF BORTEZOMIB (VELCADE) FOR RELAPSED AND
REFRACTORY MULTIPLE MYELOMA
Bagust A1, Haycox A1, Mujica-Mota
R1, Dhawan R2, Dubois D3
1 University of Liverpool, Liverpool, UK; 2
Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA;
3 Johnson & Johnson Pharmaceutical Services LLC,
Beerse, Belgium |
|
PCN4 |
COST-UTILITY
ANALYSIS OF FULVESTRANT VERSUS EXEMESTANE IN THE SECOND LINE
TREATMENT OF POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER
Ryan J1, Hirsch M2, Knight H1
1 Mapi Values Ltd, Macclesfield, Cheshire, UK; 2
AstraZeneca UK Ltd, Macclesfield, Cheshire, UK |
|
PCN5 |
COST-UTILITY
ANALYSIS OF ANASTROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN
POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (EBC): A UK
NATIONAL HEALTH SERVICE (NHS) PERSPECTIVE
Brown R1, Benedict A1, Mansel RE2
1 MEDTAP International Inc, London, UK; 2
University of Wales College of Medicine, Cardiff, UK |
|
PCN6 |
HOSPITALIZATION COSTS OF PATIENTS WITH INFECTIONS WHO HAVE LUNG
CANCER OR NEUTROPENIA IN SWEDEN – A RETROSPECTIVE DATABASE STUDY
Myren KJ
Eli Lilly Sweden AB, Solna, Sweden |
|
PCN7 |
THE LIFETIME
COST OF GEFITINIB (‘IRESSA’) IN TREATING PATIENTS WITH
NON-SMALL-CELL LUNG CANCER (NSCLC)
Haiderali A1, Chin W2
1 AstraZeneca Canada Inc, Mississauga, Ontario,
Canada; 2 Axia Research Inc, Salt Lake City, UT, USA |
|
PCN8 |
COST-EFFECTIVENESS ANALYSIS OF ORAL IBANDRONATE VERSUS IV
ZOLEDRONIC ACID OR IV GENERIC PAMIDRONATE FOR BONE METASTASES
FROM BREAST CANCER IN PATIENTS RECEIVING ORAL HORMONAL THERAPY
IN THE UK
De Cock E1, Hutton J1, Barrett-Lee
P2, Canney P3, Body JJ4, Neary
M5, Lewis G6
1 MEDTAP International Inc, London, UK; 2
Velindre Cancer Centre, Cardiff, UK; 3 Western
Hospital, Glasgow, UK; 4 Université Libre de
Bruxelles, Brussels, Belgium; 5 Hoffmann-La Roche
Inc, Nutley, NJ, USA; 6 Roche Products Limited,
Welwyn Garden City, Herts, UK |
|
PCN9 |
A
TIME-IN-MOTION STUDY OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC
ACID FOR THE TREATMENT OF METASTATIC BONE DISEASE IN BREAST
CANCER PATIENTS IN THE UK
Wardley A1, Body JJ2, Neary M3,
Lewis G4
1 Christie Hospital, Manchester, UK; 2
Université Libre de Bruxelles, Brussels, Belgium; 3
Hoffmann-La Roche Inc, Nutley, NJ, USA; 4 Roche
Products Limited, Welwyn Garden City, Herts, UK |
|
PCN10 |
COST-EFFECTIVENESS-ANALYSIS OF BREAST CANCER DIAGNOSIS WITH CAD
(COMPUTER AIDED DETECTION)
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, Germany |
|
PCN11 |
COST-EFFECTIVENESS OF ORAL IBANDRONATE VERSUS IV ZOLEDRONIC ACID
OR IV PAMIDRONATE IN THE TREATMENT OF BREAST CANCER WITH BONE
METASTASES IN PATIENTS UNDERGOING IV CHEMOTHERAPY IN THE UK
De Cock E1, Hutton J1, Barrett-Lee
P2, Canney P3, Body JJ4, Neary
M5, Lewis G6
1 MEDTAP International Inc, London, UK; 2
Velindre Cancer Centre, Cardiff, UK; 3 Western
Hospital, Glasgow, UK; 4 Université Libre de
Bruxelles, Brussels, Belgium; 5 Hoffmann-La Roche
Inc, Nutley, NJ, USA; 6 Roche Products Limited,
Welwyn Garden City, Herts, UK |
|
PCN12 |
COST
EFFECTIVENESS OF AN ASPIRIN CHEMOPREVENTION AND/OR COLONOSCOPIC
SURVEILLANCE IN THE COLORECTAL CANCER
Gerlier L1,
Launois R1, Deyra J2, Traissac L3,
Chaussade S4, Benamouzig R3
1 REES France, Paris, France; 2 APACC,
Paris, France; 3 Hôpital Avicenne, Bobigny, France;
4 Hôpital Cochin, Paris, France |
|
PCN13 |
COST-EFFECTIVENESS ANALYSIS OF ADVANCED NON-SMALL CELL LUNG
CANCER TREATMENT WITH CISPLATIN-ETOPOSIDE, CISPLATIN-WINORELBINE
AND CISPLATIN-GEMCYTABINE
Skowron A, Brandys J
Jagiellonian University, Cracow, Poland |
|
PCN14 |
ALCEA
(ADVANCED LUNG CANCER ECONOMIC ASSESSMENT)
Mangone M1, Negrini C2, Perrone F3,
Portalone L4, Salvati F5, Zorat PL6
1 Astrazeneca Italy; 2 PBE Consulting,
Verona, Italy; 3 Istituto Nazionale Tumori, Napoli,
Italy; 4 Ospedale C.Forlanini Roma, Italy; 5
Azienda Ospedaliera S. Camillo Forlanini, Roma, Italy; 6
P.O.Cŕ Foncello, Treviso, Italy |
|
PCN15 |
GEMZAR
RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIALS (GREAT2): A
PATIENT-LEVEL COST COMPARISON OF THREE CHEMOTHERAPY REGIMENS IN
THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN FRANCE
Launois R1, Avoinet S2, Le Lay K1,
Tilden D3, Bhalla S4, Kielhorn A5,
Chemali N2
1 REES France, PARIS, France; 2 LILLY,
Suresnes, France; 3 M-TAG, Chatswood, New Zealand;
4 European Health Outcomes Research, Windlesham, UK;
5 EDOS Team Leader, Windlesham, Surrey, UK |
|
PCN16 |
COMPARATIVE
COSTS OF GEMCITABINE/CISPLATIN, PACLITAXEL/CARBOPLATIN AND
VINORELBINE/CISPLATIN IN THE TREATMENT OF NON-SMALL CELL LUNG
CANCER IN GERMANY
Bischoff H1, Hamann M2, Stynes G3,
Bhalla S4, Tilden D3,
Kielhorn A4
1 Stabsstelle Medizinisches Management, Heidelberg,
Germany; 2 Eli Lilly – Germany, Bad Homburg, Germany;
3 M-TAG Limited, Hammersmith, UK; 4 Eli
Lilly, Windlesham, Surrey, UK |
|
PCN17 |
DOES
GEMCITABINE PLUS CISPLATIN PROVIDE VALUE FOR MONEY IN THE
TREATMENT OF ADVANCED NON-SMALL-CELL LUNG CANCER IN THE UK?
Watkins J1,
Kielhorn A2, Bhalla S2, Tilden D3,
Stynes G3
1 Eli Lilly, Basingstoke, UK; 2 Eli Lilly,
Windlesham, Surrey, UK; 3 M-TAG Limited, Hammersmith,
UK |
|
PCN18 |
A COST
COMPARISON OF GEMZAR PLUS CISPLATIN WITH OTHER NOVEL AGENTS IN
THE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ITALY
Kielhorn A1, Stynes G2, Bhalla S1,
Tilden D2
1 Eli Lilly, Windlesham, Surrey, UK; 2
M-TAG Limited, Hammersmith, UK |
|
PCN19 |
NEW TARGETED
THERAPY FOR PATIENTS WITH PREVIOUSLY-TREATED ADVANCED NON-SMALL
CELL LUNG CANCER – GEFITINIB (‘IRESSA’)
de Peuter R1, Antonisse A2, van
Loon J1, Brown J3
1 Mapi Values, Houten, Netherlands; 2
AstraZeneca BV, Zoetermeer, Netherlands; 3
AstraZeneca, Macclesfield, Cheshire, UK |
|
PCN20 |
COSTS OF
TREATING ADVANCED NON-SMALL-CELL LUNG CANCER IN SPAIN USING
GEMCITABINE IN COMBINATION WITH CISPLATIN: A COMPARISON WITH
OTHER 2ND GENERATION NOVEL AGENTS
Kielhorn A1, Dilla T2, Stynes G3,
Tilden D3, Bhalla S1
1 Eli Lilly, Windlesham, Surrey, UK; 2 Eli
Lilly, Madrid, Spain; 3 M-TAG Limited, Hammersmith,
UK |
|
PCN21 |
A
PHARMACOECONOMIC MODEL OF THE COST-EFFECTIVENESS OF GEFITINIB (‘IRESSA’)
COMPARED WITH BEST SUPPORTIVE CARE (BSC) IN THIRD-LINE TREATMENT
OF PATIENTS WITH REFRACTORY ADVANCED NON-SMALL-CELL LUNG CANCER
(NSCLC) IN THE UK
Ratcliffe AE1, Beard S2, Wolowacz
S2
1 AstraZeneca, Luton, Bedfordshire, UK; 2
RTI Health Solutions, Manchester, UK |
|
PCN22 |
A SYSTEMATIC
EVALUATION OF THE IMPACT OF THE SCREENING INTERVAL ON
EFFECTIVENESS AND COST-EFFECTIVENESS OF DIFFERENT CERVICAL
CANCER SCREENING TECHNIQUES.
Sroczynski G1, Aidelsburger P2,
Wasem J2, Voigt K3, Gibis B4,
Engel J5, Hillemanns P5, Hölzel D5,
Goldie SJ6, Siebert U1
1 Harvard Medical School, Boston, MA, USA; 2
University of Duisburg-Essen, Duisburg-Essen, Germany; 3
Institute for Medical Informatics, Biostatistics, and
Epidemiology, University of Munich, Munich, Germany; 4
National Association of Statutory Health Insurance Physicians,
Berlin, Germany; 5 University of Munich, Munich,
Germany; 6 Harvard School of Public Health, Boston,
USA |
|
PCN23 |
A COST
MINIMIZATION ANALYSIS OF FIRST-LINE POLYCHEMOTHERAPY REGIMENS IN
THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
Le Lay K1, Riou-França L2, Avoinet
S3, Chemali N4, Vergnenčgre A5,
Launois R6
1 Rees France, Paris, France; 2 ReesFrance,
Paris, France; 3 LILLY FRANCE, Suresnes, France;
4 Lilly, Suresnes, France; 5 Hopital Du Cluzeau,
Limoges, France; 6 ReesFrance, Paris, FRANCE, France |
|
PCN24 |
GEMZAR
RETROSPECTIVE ECONOMIC ANALYSIS OF CLINICAL TRIAL (GREAT) IN THE
TREATMENT OF NON-SMALL-CELL LUNG CANCER IN TAIWAN
Yang CH1, Wang L2, Wang N3,
Kielhorn A4
1 National Taiwan University Hospital, Taipei,
Taiwan; 2 Protech Pharmaservices Corporation, Taipei,
Taiwan; 3 Eli Lilly and Company Taiwan, Taipei,
Taiwan; 4 Eli Lilly Holdings Limited, Surrey, UK |
|
PCN25 |
COST-EFFECTIVENESS-ANALYSIS OF THE THERAPY OF STAGE T1-T2
PROSTATE CANCER WITH PERMANENT SEED IMPLANTATION IN COMPARISON
WITH RADICAL PROSTATECTOMY
Heinen-Kammerer T, Motzkat K, Rychlik R
Institute of Empirical Health Economics, Burscheid, NRW, Germany |
|
PCN26 |
WITHDRAWN |
Quality of Life/Utility/Preference Studies
|
PCN27 |
PATIENT
PREFERENCE FOR ANASTROZOLE AS ADJUVANT HORMONAL THERAPY FOR
EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE
WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J1, Burridge J1, Gniel J2,
Maclean A2, LeReun C1, Adams J1,
Davey P1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia;
2 AstraZeneca Australia Pty Ltd, NSW, Australia |
|
PCN28 |
QUALITY OF
LIFE AND SEXUALITY IN PATIENTS WITH RECTAL CANCER
Bestmann B1, Schmidt C2, Kuechler
T1, Kremer B3
1 Reference Center Quality of Life in Oncology, Kiel,
Schleswig-Holste, Germany; 2 Department of General
and Thoracic Surgery, Kiel, Schleswig-Holste, Germany; 3
University of Kiel, Kiel, Schleswig-Holste, Germany |
|
PCN29 |
PROSTATE
CANCER SPECIFIC SYMPTOMS IN A GERMAN REFERENCE POPULATION
Bestmann B1, Loetters C2, Weidner
W2, Kuechler T1, Rohde V2
1 Reference Center Quality of Life in Oncology, Kiel,
Schleswig-Holste, Germany; 2 University of Giessen,
Giessen, Hessen, Germany |
|
PCN30 |
IMPROVED
TOXICITY PROFILE OF PEMETREXED VS DOCETAXEL IN PREVIOUSLY
TREATED NON-SMALL CELL LUNG CANCER PATIENTS TRANSLATES TO COST
SAVINGS IN SPAIN
Stynes G1, Aristides M1, Rosell R2,
Felip E3, Liepa AM4
1 M-TAG Limited, London, UK; 2 Hospital
Germans Trias I Pujol, Barcelona, Spain; 3 Hospital
General Universitari Vall d’Hebron, Barcelona, Spain; 4
Eli Lilly and Company, Indianapolis, IN, USA |
|
PCN31 |
EVALUATION
OF PEMETREXED VERSUS DOCETAXEL IN THE SECOND-LINE TREATMENT OF
ADVANCED NON-SMALL CELL LUNG CANCER: PATIENT PREFERENCE AND
WILLINGNESS-TO-PAY WITH DISCRETE CHOICE CONJOINT ANALYSIS
Brown AJ1,
Aristides M1, Fitzgerald PE2,
Liepa AM3, Boyer MJ4, Clarke SA4
1 M-TAG Ltd, London, UK; 2 M-TAG Pty Ltd,
Chatswood West, New South Wales, Australia; 3 Eli
Lilly and Company, Indianapolis, IN, USA; 4 Sydney
Cancer Centre, Sydney, Australia |
|
PCN32 |
INSTRUMENTS
TO MEASURE PATIENT-REPORTED OUTCOMES AND PERCEPTIONS OF
CANCER-RELATED FATIGUE: A REVIEW OF THE LITERATURE
Baró E1,
Herdman MJ1, Gasquet JA2, Sanchez
J2
1 3D Health Research, Barcelona, Spain; 2
Amgen, Barcelona, Spain |
|
PCN33 |
HEALTH
UTILITY VALUES FOR CANCER RELATED ANAEMIA
Lloyd A1, Kimberley S1, Cornes P2,
Tolley K3
1 MEDTAP International, London, UK; 2
Royal United Hospital Bath, Bath, UK; 3 ORTHO
BIOTECH, Buckinghamshire, UK |
|
PCN34 |
UTILITY
ASSOCIATED WITH SEVERITY OF CANCER-RELATED ANAEMIA (CRA): A
SOCIETAL VALUATION
Ossa DF1, Briggs A2, Cowell W3,
Littlewood T4, Sculpher M5
1 Occam Outcomes, Oxford, UK; 2 HERC –
University of Oxford, Oxford, UK; 3 Healthcare
Management Group – Roche, Welwyn Garden City, UK; 4
John Radcliffe Hospital, Oxford, UK; 5 University of
York, York, UK |
|
PCN35 |
VALUATION OF
SOCIETAL PREFERENCE BETWEEN THERAPIES FOR CANCER-RELATED ANAEMIA
(CRA): RECOMBINANT HUMAN ERYTHROPOETIN (RH-EPO) VERSUS BLOOD
TRANSFUSION
Ossa DF1, McIntosh E2, Briggs A2,
Cowell W3, Littlewood T4, Sculpher M5
1 Occam Outcomes, Oxford, UK; 2 HERC –
University of Oxford, Oxford, UK; 3 Healthcare
Management Group – Roche, Welwyn Garden City, UK; 4
John Radcliffe Hospital, Oxford, UK; 5 University of
York, York, UK |
Health Policy Studies
|
PCN36 |
THE VALUE OF
THE USE OF ANASTROZOLE AS AN ALTERNATIVE ADJUVANT THERAPY FOR
EARLY BREAST CANCER (EBC) USING DISCRETE CHOICE
WILLINGNESS-TO-PAY (WTP) METHODOLOGY
Wilson J1, Burridge J1, Gniel J2,
Maclean A2, LeReun C1, Adams J1,
Davey P1
1 M-TAG Australia Pty Ltd, Chatswood, NSW, Australia;
2 AstraZeneca Australia Pty Ltd, NSW, Australia |
|
PCN37 |
DIFFERENCES
IN TREATMENT PRACTICE, RESPONSE RATES AND COST OF EPOETIN ALFA
AND DARBEPOETIN ALFA TREATMENT FOR ANEMIC CANCER PATIENTS: A
RETROSPECTIVE ANALYSIS FROM SWEDEN
Persson U1, Borg S1, Jansson S1,
Ekman T2, Franksson L3, Friesland S3,
Larsson AM4
1 IHE, The Swedish Institute for Health Economics,
Lund, Sweden; 2 Sahlgrenska University Hospital,
Gothenburg, Sweden; 3 Karolinska Institutet,
Karolinska University Hospital, Stockholm, Sweden; 4
University Hospital, Malmö, Sweden |
|
PCN38 |
THE IMPACT
OF SCREENING ADHERENCE ON MEDICAL EFFECTIVENESS AND
COST-EFFECTIVENESS OF CERVICAL CANCER SCREENING IN GERMANY – A
DECISION ANALYSIS
Sroczynski G1, Voigt K2, Gibis B3,
Aidelsburger P4, Engel J5, Wasem J4,
Hillemanns P5, Hölzel D5, Goldie SJ6,
Siebert U1
1 Harvard Medical School, Boston, MA, USA; 2
Institute for Medical Informatics, Biostatistics, and
Epidemiology, University of Munich, Munich, Germany; 3
National Association of Statutory Health Insurance Physicians,
Berlin, Germany; 4 University of Duisburg-Essen,
Duisburg-Essen, Germany; 5 University of Munich,
Munich, Germany; 6 Harvard School of Public Health,
Boston, USA |
|
PCN39 |
QUALITY
ASSURANCE IN CANCER CHEMOTHERAPY THROUGH PHARMACEUTICAL CARE
DOCUMENTATION
Simons S1, Hudson SA2, Macintyre J3,
Maclean M4, Jaehde U1
1 Rheinische Friedrich-Wilhelms-Universitaet Bonn,
Bonn, NRW, Germany; 2 University of Strathclyde,
Glasgow, Glasgow, UK; 3 Western General Hospital,
Edinburgh, UK; 4 Western Infirmary, Glasgow, UK |
|
PCN40 |
DISPARITIES
IN MEDICAID CANCER EXPENDITURES
Mullins CD, Snyder SE, Wang J, Cooke JL, Baquet CR
University of Maryland, Baltimore, MD, USA |
|
PCN41 |
ASSESSMENT
OF DIFFERENT STRATEGIES FOR DETERMINING DIAGNOSIS AND
RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER
Schink T1, Boehmig M1, Hur C2,
Rosewicz S1, Wernecke KD1, Siebert U2
1 Charité University Hospital, Berlin, Germany;
2 Harvard Medical School, Boston, MA, USA |
Methods
|
PCN42 |
POOLING
CLINICAL AND COST OUTCOMES: A CASE STUDY OF BEST SUPPORTIVE CARE
(BSC) IN ADVANCED NON SMALL CELL LUNG CANCER (NSCLC)
McAllister R1, Meddis D2, Jansen J1,
Ryan J1, Brown J2
1 MAPI Values Ltd, Bollington, Cheshire, UK; 2
AstraZeneca, Macclesfield, Cheshire, UK |
|
PCN43 |
MAPPING
HEALTH-RELATED QUALITY OF LIFE (HRQOL) MEASUREMENTS INTO GENERIC
UTILITY MEASURES (EQ-5D): A CASE STUDY WITH BORTEZOMIB (VELCADE)
Mujica-Mota R1, Bagust A1, Haycox
A1, Dhawan R2, Dubois D3
1 University of Liverpool, Liverpool, UK; 2
Johnson & Johnson Pharmaceutical Services LLC, Raritan, NJ, USA;
3 Johnson & Johnson Pharmaceutical Services LLC,
Beerse, Belgium |
|
PCN44 |
META-ANALYSIS OF THE DIAGNOSTIC ACCURACY OF SCREENING TESTS FOR
COLORECTAL CANCER
Slivinskas J1,
Gagnon YM1, Enns R2
1 Occam Outcomes Ltd, Vancouver, BC, Canada; 2
St. Paul's Hospital, University of British Columbia, Vancouver,
BC, Canada |
|
PCN45 |
MODELING
EFFECT IN PHARMACOECONOMICS ANALYSIS USING ARTIFICIAL NEURAL
NETWORKS
Polak S, Skowron A, Brandys J, Mendyk A
Jagiellonian University, Kraków, Maopolska, Poland |
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Clinical Outcomes
Studies
|
PCO1 |
|
DRUG USE
PROFILES AFTER HOSPITALIZATION FOR CHRONIC OBSTRUCTIVE PULMONARY
DISEASE (COPD) IN THE NETHERLANDS AND THE RISK ON
RE-HOSPITALIZATION
Janse AFC1, Breekveldt-Postma NS1,
Erkens JA1, Sandtmann R2, Melilli LE3,
Herings RMC4
1 PHARMO Institute, Utrecht, Netherlands; 2
Altana Pharma AG, Konstanz, Germany; 3 Pfizer Inc,
New York, NY, USA; 4 PHARMO Institute / Utrecht
Institute for Pharmaceutical Sciences, Utrecht University,
Utrecht, Netherlands |
|
Methods
|
PCO2 |
|
ITEM
SELECTION FOR COPD-SPECIFIC UTILITY INSTRUMENT
Meguro M, Jones PW
St George's Hospital Medical School, London, UK |
|
|
PCO3 |
|
DEVELOPMENT
OF A COPD SEVERITY SCORE IN CLAIMS DATABASE
Wu EQ1, Birnbaum HG1,
Cifaldi M2, Colice G3, Kang Y1
1 Analysis Group Inc, Boston, MA, USA; 2
Abbott Laboratories, Abbott Park, IL, USA; 3
Washington Hospital Center, Washington, DC, USA |
|
CARDIOVASCULAR DISEASES
Clinical Outcomes Studies
|
PCV1 |
THE
COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF
HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN
TAIWAN.
Yang WC1, Annemans L2, Ng YY1,
Hwang SJ3
1 Taipei Veterans General Hospital, Taipei, Taiwan;
2 Ghent University, Meise, Belgium; 3
Kaohshiung Medical University Hospital, Kaohsiung, Taiwan |
|
|
PCV2 |
ACHIEVEMENT
OF THE EUROPEAN 1998 LDL-C GOAL BY HYPERCHOLESTEROLAEMIC
PATIENTS IN THE STELLAR TRIAL: AN EVIDENCE-BASED MEDICINE (EBM)
APPROACH
Edwards SJ, Hadlow S
AstraZeneca UK Ltd, Luton, Bedfordshire, UK |
|
|
PCV3 |
TIME TO LDL-CHOLESTEROL
GOAL ATTAINMENT IN SPAIN
Olivares Q1, Mabe I2, Nocea G3,
Alemao E4, Caloto T3, Fosbrook L5,
Ahumada C5, Yin D4
1 CS Pedro La Mata, Albacete, Spain; 2 CS
Bidezabal, Vizcaya, Spain; 3 Merck, Sharp & Dohme de
Espańa, Madrid, Spain; 4 Merck & Co, Whitehouse
Station, NJ, USA; 5 Schering Plough, Madrid, Spain |
|
|
PCV4 |
FIRST
ANALYSIS OF CLINICAL SIGNIFICANT INTERACTIONS IN HIGH-RISK
CARDIOVSCULAR PATIENTS ENROLLED INTO HOPE-TOO TRIAL IN SLOVAKIA
IN THE THIRD YEAR OF TRIAL PARTICIPATION
Foltanova T1, Thurzo M2, Lietava J2,
Tumova I1, Lonn E3, Fodor JG4
1Faculty of Pharmacy, Comenius University,
Bratislava, Slovakia; 2 2-nd Department of Internal
Medicine, Comenius University, Bratislava, Slovakia; 3Hamilton
University, Hamilton, ON, Canada; 4University of Ottawa
Heart Institute, Ottawa, Canada |
|
Cost Studies
|
PCV79 |
THE
COST-EFFECTIVENESS OF IRBESARTAN IN THE TREATMENT OF
HYPERTENSIVE TYPE 2 DIABETIC PATIENTS WITH MICROALBUMINURIA IN
CHINA
Hu S1, Chen W1, Annemans L2
1 Fudan University, Shanghai, China; 2
HEDM, Meise, Belgium |
|
|
PCV5 |
LONG-TERM
COST-EFFECTIVENESS OF CLOPIDOGREL® IN PATIENTS WITH ACUTE
CORONARY SYNDROME WITHOUT ST-SEGMENT ELEVATION IN GERMANY
Brüggenjürgen B1, Ehlken B2
1 Alpha Care GmbH, Celle, Germany; 2 MERG,
Medical Economics Research Group, Munich, Germany |
|
|
PCV6 |
AN ECONOMIC
EVALUATION OF CLOPIDOGREL VS. ASPIRIN IN SECONDARY PREVENTION OF
ISCHEMIC EVENTS IN HIGH RISK ATHEROTHROMBOTIC PATIENTS IN ITALY
Rudelli G1, Annemans L2, Spiesser
J3, Novelli M4, Walker A5,
Gabriel S3
1 Sanofi-Synthelabo, Milan, Italy; 2 HEDM,
Meise, Belgium; 3 Sanofi-Synthelabo Recherche,
Bagneux, France; 4 Bristol-Myers Squibb, Roma, Italy;
5 Bristol-Myers Squibb, Rueil-Malmaison, France |
|
|
PCV7 |
THE
COST-EFFECTIVENESS OF CLOPIDOGREL IN ACUTE CORONARY SYNDROMES
WITHOUT ST-SEGMENT ELEVATION IN POLAND
Pietrasik A1, Niewada M1, Spiesser
J2, Gabriel S3
1 Medical University of Warsaw, Warsaw, Poland;
2 Sanofi-Synthelabo Recherche, Bagneux, France; 3
Sanofi-Synthélabo, Bagneux, France |
|
|
PCV8 |
THE ECONOMIC
IMPACT OF CLOPIDOGREL IN PATIENTS WITH UNSTABLE CORONARY ARTERY
DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTIONS (PCI):
POLISH PERSPECTIVE
Pietrasik A1, Niewada M1, Spiesser
J2, Gabriel S3
1 Medical University of Warsaw, Warsaw, Poland;
2 Sanofi-Synthelabo Recherche, Bagneux, France; 3
Sanofi-Synthélabo, Bagneux, France |
|
|
PCV9 |
COST-EFFECTIVENESS ANALYSIS OF ALTEPLASE COMPARED WITH
STREPTOKINASE AND ABSENCE OF THROMBOLYTICAL THERAPY FOR
MYOCARDIAL INFARCTION
Derkach E, Avxentieva M, Vorobjov P
Moscow medical academy, Moscow, Russia |
|
|
PCV10 |
THE
COST-EFFECTIVENESS OF CLOPIDOGREL IN PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN: AN ANALYSIS OF PCI-CURE
Lindgren P1, Stenestrand U2,
Malmberg K3, Jönsson B4
1 Stockholm Health Economics, Stockholm, Sweden;
2 University Hospital of Linköping, Linköping, Sweden;
3 Karolinska Hospital, Stockholm, Sweden; 4
Stockholm School of Economics, Stockholm, Sweden |
|
|
PCV11 |
COST
EFFECTIVENESS OF ADDING NIASPAN TO ATORVASTATIN TREATMENT IN THE
SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN PATIENTS WITH
DYSLIPIDEMIA IN THE UK
Berger W1, Roze S2, Valentine WJ2,
Palmer AJ2
1 Merck KGaA, Darmstadt, Germany; 2 CORE
Center for Outcomes Research, Binningen/Basel, Switzerland |
|
|
PCV12 |
SECONDARY
PREVENTION AFTER PCI: THE COST-EFFECTIVENESS OF FLUVASTATIN
THERAPY IN THE NETHERLANDS
Chaplin S1, Scuffham P1, Alon M2,
Boom van den G2
1 University of York, York, UK; 2 Novartis
Pharma, Arnhem, Netherlands |
|
|
PCV13 |
ECONOMIC
ASSESSMENT OF EZETIMIBE CO-ADMINISTRATION IN A HUNGARIAN CHD
PATIENT COHORT NOT AT CHOLESTEROL GOAL ON SIMVASTATIN
MONOTHERAPY
Hoffer G1, Yin D2, Alemao E2,
Nagy L3, Monori M4, Davies GM5,
Cook JR5
1 University of Debrecen, Debrecen, Hungary; 2
Merck & Co, Whitehouse Station, NJ, USA; 3 MSD
Hungary Kft, Budapest XII, Hungary; 4 Schering
Plough, Budapest, Hungary; 5 Merck & Co., Inc, Blue
Bell, PA, USA |
|
|
PCV14 |
AN ECONOMIC
ANALYSIS OF CATHETER ABLATION FOR THE TREATMENT OF VENTRICULAR
TACHYCARDIA
Reyes C1, Hernandez J1, Duff S2,
Knight T2, Calkins H3
1 Boston Scientific, San Jose, CA, USA; 2
Covance Health Economics & Outcomes Services, Gaithersburg, MD,
USA; 3 Johns Hopkins Hospital, Baltimore, MD, USA |
|
|
PCV15 |
COST-EFFECTIVENESS OF LOSARTAN IN PATIENTS WITH HYPERTENSION AND
LVH IN SPAIN: AN ECONOMIC EVALUATION BASED ON THE LIFE TRIAL
Ruilope LM1,
Burke TA2, Carides GW3, Nocea G4
1 Hospital 12 de Octubre, Madrid, Spain; 2
Merck & Co, Inc, Whitehouse Station, NJ, USA; 3 Merck
Research Labs, Blue Bell, PA, USA; 4 MSD Spain,
Madrid, Spain |
|
|
PCV16 |
EVOLUTION OF
PRESCRIPTIONS AND DRUG COSTS IN HYPERTENSION – RESULTS FROM A
DATABASE FOLLOW-UP STUDY
Berger W1, Annemans L2
1 Merck KgaA, Darmstadt, Germany; 2 Ghent
University, HEDM, Meise, Belgium |
|
|
PCV17 |
COSTS OF
HYPERTENSION IN POLAND MEASURED FROM THE THIRD PARTY PAYER
PERSPECTIVE IN COMPARISON WITH THE SOCIETAL PERSPECTIVE
Hermanowski T1, Jaworski R2,
Czech M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland;
2 Servier Polska, Warsaw, Poland |
|
|
PCV18 |
COSTS OF
HYPERTENSION IN THE ELDERLY IN COMPARISON WITH PATIENTS UNDER 65
IN POLAND
Hermanowski T1, Jaworski R2, Czech
M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland;
2 Servier Polska, Warsaw, Poland |
|
|
PCV19 |
COST-EFFECTIVENESS ANALYSIS OF THE MANAGEMENT OF ARTERIAL
HYPERTENSION
Stafilas PC1, Sarafidis PA1,
Lasaridis AN1, Aletras VH2, Zouka MD3
1 AHEPA University Hospital, Thessaloniki, Greece;
2 Hellenic Open University, Patra, Greece; 3
Aristotle University of Thessaloniki, Thessaloniki, Greece |
|
|
PCV20 |
COST
EFFECTIVENESS OF ANTIHYPERTENSIVE MONO-THERAPY WITH PERINDOPRIL
OR ENALAPRIL IN ELDERLY PATIENTS FROM THE THIRD PARTY PAYER
PERSPECTIVE
Hermanowski T1,
Jaworski R2, Czech M2, Pachocki R2
1 Warsaw University of Technology, Warsaw, Poland;
2 Servier Polska, Warsaw, Poland |
|
|
PCV21 |
ECONOMIC
EVALUATION OF VARIOUS ANTIHYPERTENSIVE MONOTHERAPIES IN GREECE
Stafilas PC1, Zouka MD2, Sarafidis
PA1, Lasaridis AN1, Aletras VH3
1 AHEPA University Hospital, Thessaloniki, Greece;
2 Aristotle University of Thessaloniki, Thessaloniki,
Greece; 3 Hellenic Open University, Patra, Greece |
|
|
PCV22 |
THE COST
EFFECTIVENESS OF HORMONE REPLACEMENT THERAPY (HRT) FOR WOMEN
WITH MENOPASUAL SYMPTOMS IN SWEDEN
Borgström F1, Zethraeus N2,
Johnell O3, Kanis J4, Jönsson B2
1 Stockholm Health Economics, Stockholm, Sweden;
2 Stockholm School of Economics, Stockholm, Sweden; 3
Malmö University Hospital, Malmö, Sweden; 4
University of Sheffield, Sheffield, UK |
|
|
PCV23 |
ACUTE COSTS
OF STROKE IN THE UK NATIONAL HEALTH SERVICE IN 2002-2004
Luengo-Fernandez R1, Gray A1,
Mehta Z2, Rothwell P2
1 Oxford University, Oxford, Oxfordshire, UK; 2
Oxford University, UK |
|
|
PCV24 |
PHARMACOECONOMIC EVALUATION OF THE CIBIS-II TRIAL
Di Stasi F, Scalone L, Mantovani LG
University of Milan, Milan, Italy |
|
|
PCV25 |
SMOKING
CESSATION FOR PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE: A
COST-EFFECTIVENESS ANALYSIS
Der Kinderen AJ, Franco OH, De Laet C
Department of Public Health, Erasmus MC, University Medical
Center Rotterdam, Rotterdam, Netherlands |
|
|
PCV26 |
THE
COST-EFFECTIVENESS OF EXTENDED ANTITHROMBOTIC PROPHYLAXIS
FOLLOWING TOTAL HIP ARTHROPLASTY
Skedgel CD1, Goeree R2, Anderson
DR1
1 Dalhousie University, Halifax, NS, Canada; 2
McMaster University, Hamilton, ON, Canada |
|
|
PCV27 |
COST-EFFECTIVENESS OF BUPROPION IN SMOKING CESSATION IN FINLAND
Hahl J, Jormanainen V
GlaxoSmithKline Oy, Espoo, Finland |
|
|
PCV28 |
COST-EFFECTIVENESS OF RAMIPRIL IN PATIENTS AT HIGH RISK FOR
CARDIOVASCULAR EVENTS: A SWISS PERSPECTIVE
Sendi P1, Russ W2, Battegay E3,
Bucher H1
1 Institute for Clinical Epidemiology, Basel,
Switzerland; 2 Aventis Pharma AG, Zurich,
Switzerland; 3 Outpatient Department of Internal
Medicine, Basel, Switzerland |
|
|
PCV29 |
COST-EFFECTIVENESS OF REDUCTION IN CARDIOVASCULAR OUTCOMES WITH
ATORVASTATIN IN PATIENTS WITH NORMAL TO MILDLY ELEVATED
CHOLESTEROL LEVELS, TREATED FOR HYPERTENSION: THE ASCOT-LLA
STUDY
Lindgren P1, Buxton MJ2, Kahan T3,
Poulter N4, Dahlöf B5, Sever P4,
Wedel H6, Jönsson B7
1 Stockholm Health Economics, Stockholm, Sweden;
2 Brunel University, UXBRIDGE, Middlesex, UK; 3
Karolinska Institutet, Stoockholm, Sweden; 4 Imperial
College, London, UK; 5 Sahlgrenska University
Hospital/Östra, Göteborg, Sweden; 6 Nordic School of
Public Health, Göteborg, Sweden; 7 Stockholm School
of Economics, Stockholm, Sweden |
|
|
PCV30 |
COST-EFFECTIVENESS OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE
IN THE DIAGNOSTIC ASSESSMENT AND MANAGEMENT OF PATIENTS WITH
DYSPNEA IN THE EMERGENCY DEPARTMENT
Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle
GS
Harvard Medical School, Boston, MA, USA |
|
|
PCV31 |
COST OF
IN-PATIENT CARE AFTER ADMISSION FOR WARFARIN ASSOCIATED ADVERSE
DRUG REACTIONS
Ofori B1, Donnan P1, Goudie B2,
Timoney A2, Davey P1
1 University of Dundee, Dundee, UK; 2 NHS
Tayside, Dundee, UK |
|
|
PCV32 |
SOCIOECONOMIC RELEVANCE OF TREATMENT OF CHRONIC HEART FAILURE
STAGE NYHA II WITH CRATAEGUS EXTRACT WS® 1442 – A PROSPECTIVE
3-YEAR PHARMACOECONOMIC STUDY
Rychlik R1, Pfeil T1, Daniel D1,
Habs M2, Klapper HG2
1 Institute of Empirical Health Economics, Burscheid,
Germany; 2 Dr. Willmar Schwabe Arzneimittel,
Karlsruhe, Germany |
|
|
PCV33 |
MODELING THE
ECONOMIC IMPACT OF NEW IMPLANTABLE DEFIBRILLATORS WITH A LONGER
LIFETIME
Lamarsalle L1, Vainchtock A2, Le
Heuzey JY3, Matalon C4, Hazard JR4
1 GYD nstitute – division of IMS Health, Lyon,
France; 2 GYD nstitute – division of IMS Health;
3 Hôpital Européen Georges Pompidou; 4 Guidant
France SAS |
|
|
PCV34 |
COST-EFFECTIVENESS OF ANTICOAGULATION WITH BIVALIRUDIN VS.
HEPARIN AND GLYCOPROTEIN INHIBITORS IN PATIENTS UNDERGOING
PERCUTANEOUS CORONARY INTERVENTION IN SWEDEN.
Borg S1, Persson U1, Conradson TB2,
Ericsson K2
1 Swedish Institute for Health Economics, Lund,
Sweden; 2 Nycomed Group, DK-4000 Roskilde, Denmark |
|
|
PCV35 |
ECONOMIC
ASSESSMENT OF SWITCHING TO EZETIMIBE CO-ADMINISTERED WITH
SIMVASTATIN IN SPAIN FOR A COHORT OF PATIENTS NOT AT GOAL ON
ATORVASTATIN MONOTHERAPY
Davies GM1, Alemao E2, Nocea G3,
Yin D2, Cook JR1
1 Merck & Co., Inc, Blue Bell, PA, USA; 2
Merck & Co, Whitehouse Station, NJ, USA; 3 Merck,
Sharp & Dohme de Espańa, Madrid, Spain |
|
|
PCV36 |
ECONOMIC
EVALUATION OF PRIMARY PREVENTION OF CVD EVENTS WITH STATINS IN
ITALY
Bustacchini S1, Ruffo P1,
Mantovani LG2
1 Pfizer Italia srl, Rome, Italy; 2
University of Milan, Milan, Italy |
|
|
PCV37 |
ECONOMIC
EVALUATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY (TEE) GUIDED
CARDIOVERSION IN THE ANTICOAGULATION IN CARDIOVERSION USING
ENOXAPARIN (ACE) TRIAL FROM THE PERSPECTIVE OF STATUTORY HEALTH
INSURANCE (SHI) IN GERMANY
Schädlich PK1, Lehmacher W2,
Huppertz E3, Grewe R3, Brecht JG1
1 InForMed GmbH – Outcomes Research and Health
Economics, Ingolstadt, Bavaria, Germany; 2 Institute
for Medical Statistics, Informatics, and Epidemiology of the
University of Cologne, Cologne, NRW, Germany; 3
Aventis Pharma Deutschland GmbH, Bad Soden am Taunus, Hesse,
Germany |
|
|
PCV38 |
COSTS OF
MYOCARDIAL INFARCTION TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobjov P, Sura M
Moscow Medical Academy, Moscow, Russia |
|
|
PCV39 |
MODELING THE
ECONOMIC CONSEQUENCES OF IMPLANTING DUAL CHAMBER VS. SINGLE
CHAMBER PACEMAKERS IN THE UK
Caro JJ, Ward AJ
Caro Research Institute, Concord, MA, USA |
|
|
PCV40 |
COSTS OF
ISCHEMIC STROKE TREATMENT IN RUSSIAN FEDERATION
Avxentieva M, Vorobyov P, Sura M
Moscow medical academy, Moscow, Russia |
|
|
PCV41 |
COST-EFFECTIVENESS OF PHARMACEUTICAL TREATMENTS OF
HYPERCHOLESTEROLEMIA IN CATALONIA, SPAIN
Plans-Rubió P
Departament de Sanitat of Catalonia, Barcelona, Spain |
|
|
PCV42 |
WITHDRAWN |
|
|
PCV43 |
THE IMPACT
OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) ENOXAPARIN USAGE ON
OUTCOMES OF TREATMENT MANAGEMENT OF PATIENTS WITH ACUTE CORONARY
SYNDROMES (ACS) IN RUSSIA
Vorobiov PA1, Yavelov IS2, Pavlov
VE3
1 Russian Society of Pharmacoeconomics and Outcomes
Research, Moscow, Russia; 2 Scientific Institute of
Physical and Chemical Medicine, Moscow, Russia; 3
Aventis Pharma, Moscow, Russia |
|
|
PCV44 |
VKA
TREATMENT RELATED COSTS IN FRANCE IN PATIENTS WITH CHRONIC
NONVALVULAR ATRIAL FIBRILLATION : COST DATA FROM THE
INTERNATIONAL STUDY OF ANTICOAGULATION MANAGEMENT (ISAM)
Drouet L1, Duru G2, Mahé I1,
Bergmann JF1, Bal dit Sollier C1,
Lamarque H3, Gauchoux R4, Woessner
M3, Hollowell J5
1 Hôpital Lariboisičre, Paris, France; 2
Université C. Bernard Lyon I, Villeurbanne, France; 3
AstraZeneca, Rueil Malmaison, France; 4 Naxis, Lyon,
France; 5 AstraZeneca, Molndal, Sweden |
|
|
PCV45 |
A SHORT-TERM
RETROSPECTIVE ECONOMIC EVALUATION FOR THE TREATMENT OF MILD TO
MODERATE ESSENTIAL HYPERTENSION WITH ANGIOTENSIN II-ANTAGONISTS
IN SPAIN.
Calvo C1, López Paz JE1, González P2,
Del Castillo A3, Rejas J3
1 University Hospital of Santiago de Compostela;
2 Euroclin Institute; 3 Health Outcomes
Research, Medical Unit, Pfizer SA, Alcobendas, Madrid, Spain |
|
|
PCV46 |
SCREENING
FOR ABDOMINAL AORTIC ANEURYSM IN MEN. AN ECONOMIC EVALUATION
BASED ON A SYSTEMATIC REVIEW OF THE LITERATURE
Wanhainen A1,
Lundkvist J2, Bergqvist D1, Björck
M1
1 Uppsala University Hospital, Uppsala, Sweden;
2 Karolinska Institutet, Stockholm, Sweden |
|
|
PCV47 |
DECISION
ANALYSIS ON EFFECTIVENESS AND COST-EFFECTIVENESS OF DISEASE
MANAGEMENT PROGRAMS FOR THE TREATMENT OF HEART FAILURE
Goehler A1, Dietz R1, Osterziel KJ1,
Siebert U2
1 Charitč Campus Virchow Klinikum, Berlin, Germany;
2 Harvard Medical School, Boston, MA, USA |
|
|
PCV48 |
ARIAL
FIBRILLATION HISTORY AND ATRIOVENTRICULAR BLOCK APPEARANCE IN
PATIENTS WITH SINUS NODE DISEASE AND SINGLE CHAMBER ATRIAL
PACEMAKER – IMPACT ON COST OF THERAPY
Rucinski P1, Kutarski A2
1 Medical University of Lublin, Lublin, Poland,
Poland; 2 Medical University of Lublin, Lublin,
Poland |
|
Quality of
Life/Utility/Preference Studies
|
PCV49 |
CHRONIC
VENOUS DISEASE AND DEPRESSIVE SYMPTOMATOLOGY
Guex JJ1, Myon E2, Marionneau N2,
Taieb C2
1 Societe Francaise de Phlebologie, Nice, France;
2 Health Economics & Quality of Life Dept,
Boulogne-Billancourt, France |
|
|
PCV50 |
CHRONIC
VENOUS DISEASE: PATIENTS PROFILE
Guex JJ1, Myon E2, Marionneau N2,
Taieb C2
1 Societe Francaise de Phlebologie, Nice, France;
2 Health Economics & Quality of Life Dept,
Boulogne-Billancourt, France |
|
